Frequencies of C282Y and H63D alleles in the HFE gene among various Jewish ethnic groups in Israel: A change of concept required

Genetics in Medicine

Volumn 12, Issue 2, 2010, Pages 122-125

  Reish, Orit ^a,b   Shefer Kaufmann, Niva ^c   Shimshoni, Daphne Chapman ^a   Renbaum, Paul ^d   Orr Urtreger, Avi ^b,c   Steiner, Hillel ^d   Rapoport, Micha ^a,b   Levy Lahad, Ephrat ^d,e   Altarescu, Gheona ^d,e  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d SHAARE ZEDEK MEDICAL CENTER   (Israel)

^e HEBREW UNIVERSITY   (Israel)

Author keywords

Allele frequency; Hereditary hemochromatosis; HFE gene; Non Ashkenazi Jews; Population study

Indexed keywords

HFE PROTEIN;

ADOLESCENT; ADULT; ALLELE; ARTICLE; BETA THALASSEMIA; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; ETHNIC GROUP; FAMILY ASSESSMENT; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENOTYPE; HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD; JEW; MALE; NORTH AFRICA;

EID: 77149125568     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181cb78d6     Document Type: Article

References (37)

1. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
2. Mura C, Raguenes O, Ferec C. HFE mutations analysis in 711 hemochro-matosis probands: evidence for S65C implication in mild form of hemo-chromatosis. Blood 1999;93:2502-2505.
3. Ostrer HA. Genetic profile of contemporary Jewish populations. Nat Rev Genet 2001;2:891-897.
4. Kedar-Barnes I, Rozen P. The Jewish people: their ethnic history, genetic disorders and specific cancer susceptibility. Fam Cancer 2004;3:193-199.
5. Ben-Sasson HH, Malamat A, Tadmor H. A history of the Jewish people. Cambridge, MA: Harvard University Press, 1976.
6. Beutler E, Gelbart T. HLA-H mutations in the Ashkenazi Jewish population. Blood Cells Mol Dis 1997;23:95-98.
7. Matas M, Guix P, Castro JA, et al. Prevalence of HFE C282Y and H63D in Jewish populations and clinical implications of H63D homozygosity. Clin Genet 2006;69:155-162.
8. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997;34: 275-278.
9. Goland S, Kaftouri BN, Shimoni A, Caspi S, Malnick SD. Hemochromatosis mutations are not linked to dilated cardiomyopathy in Israeli patients. Eur J Heart Failure 2004;6:547-550.
10. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
11. Lynas C. A cheaper and more rapid polymerase chain reaction-restriction fragment length polymorphism method for the detection of the HLA-H gene mutations occurring in hereditary hemochromatosis. Blood 1997;90: 4235-4236.
12. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N EnglJ Med 2005;352: 1769-1778.
13. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-724.
14. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. Genet Test 2000;4: 183-198.
15. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221-230.
16. Ropero P, Briceño O, Mateo M, et al. Frequency of the C282Y and H63D mutations of the hemochromatosis gene (HFE) in a cohort of 1000 neonates in Madrid (Spain). Ann Hematol 2006;85:323-326.
17. Rochette J, Pointon JJ, Fisher CA, et al. Multicentric origin of hemochromatosis gene (HFE) mutations. Am J Hum Genet 1999;64:1056-1062.
18. Cullen LM, Gao X, Easteal S, et al. The hemochromatosis 845 G->A and 187 C->G mutations: prevalence in non-Caucasian populations. Am J Hum Genet 1998;62:1403-1407.
19. Asberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001;36:1108-1115.
20. Delatycki MB, Allen KJ, Nisselle AE, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 2005;366:314-316.
21. Adams PC, Barton JC. Haemochromatosis. Lancet 20071;370:1855-1860.
22. Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med 2005;143:522-536.
23. Burke W, Imperatore G, McDonnell SM, Baron RC, Khoury MJ. Contribution of different HFE genotypes to iron overload disease: a pooled analysis. Genet Med 2000;2:271-277.
24. Aguilar-Martinez P, Bismuth M, Picot MC, et al. Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause? Gut 2001;48:836-842.
25. Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000;133:329-337.
26. Mura C, Nousbaum JB, Verger P, et al. Phenotype-genotype correlation in haemochromatosis subjects. Hum Genet 1997;101:271-276.
27. Carella M, D'Ambrosio L, Totaro A, et al. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet 1997;60:828-832.
28. Bukvic N, Sportelli F, Sessa F, et al. Coexistence of beta-thalassemia and hereditary hemochromatosis in homozygosity: a possible synergic effect? Hemoglobin 2009;33:155-157.
29. Martins R, Picanco I, Fonseca A, Ferreira L, et al. The role of HFE mutations on iron metabolism in beta-thalassemia carriers. J Hum Genet 2004;49:651-655.
30. Yamsri S, Sanchaisuriya K, Fucharoen S, et al. H63D mutation of the hemochromatosis gene and serum ferritin levels in Thai thalassemia carriers. Acta Haematol 2007;118:99-105.
31. Ruiz-Arguelles GJ, Garces-Eisele J, Reyes-Nuñez V, et al. Heterozygosity for the H63D mutation in the hereditary hemochromatosis (HFE) gene may lead into severe iron overload in beta-thalassemia minor: observations in a thalassemic kindred. Rev Invest Clin 2001;53:117-120.
32. Melis MA, Cau M, Deidda F, Barella S, Cao A, Galanello R. H63D mutation in the HFE gene increases iron overload in beta-thalassemia carriers. Haematologica 2002;87:242-245.
33. Filon D, Oron V, Krichevski S, et al. Diversity of /3-globin mutations in Israeli ethnic groups reflects recent historic events. Am J Hum Genet 1994; 54:836-843.
34. Rund D, Filon D, Doewling CE, Rachmilewitz E, Kazazian HH Jr, Oppen-heim A. Diversity of molecular lesions causing beta B-thalassemia in Israel Jewish ethnic groups. In: Adam A, Bonne Tamir B, editors. New perspectives in genetic markers and diseases among the Jewish people. Cambridge, MA: Oxford Press, 1992:228-236.
35. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004;127:S79-S86.
36. Barton JC, Bertoli LF, Acton RT. HFE C282Y and H63D in adults with malignancies in a community medical oncology practice. BMC Cancer 2004;4:6.
37. Deugnier Y, Turlin B. Iron and hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:491-494.